Zacks Investment Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,309
Closed -$234K 742
2025
Q4
$234K Buy
+2,309
New +$185K ﹤0.01% 639
2024
Q4
Sell
-30,579
Closed -$2.08M 700
2024
Q3
$2.08M Buy
+30,579
New +$1.73M 0.02% 340
2024
Q1
Sell
-59,862
Closed -$4.43M 666
2023
Q4
$4.43M Sell
59,862
-706
-1% -$46.3K 0.05% 194
2023
Q3
$4.13M Buy
60,568
+1,375
+2% +$117K 0.05% 201
2023
Q2
$5.56M Buy
+59,193
New +$4.62M 0.07% 175
2018
Q1
Sell
-35,498
Closed -$1.86M 549
2017
Q4
$1.86M Buy
+35,498
New +$1.9M 0.04% 280
2017
Q2
Sell
-29,761
Closed -$703K 625
2017
Q1
$703K Buy
+29,761
New +$590K 0.02% 428

Other funds holding EXAS

Zacks Investment Management's EXAS Position: Q1 2026 in Review

Zacks Investment Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 2,309 shares — an estimated $234K sold.

Zacks Investment Management first reported a position in EXAS in Q1 2017 and held it in 7 quarters. The position peaked at $5.56M in Q2 2023. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Zacks Investment Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Zacks Investment Management sold 2,309 Exact Sciences shares in Q1 2026, an estimated $234K.
  • Zacks Investment Management first reported a position in Exact Sciences in Q1 2017 and held it in 7 quarters.
  • Zacks Investment Management's Exact Sciences position peaked at $5.56M in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.